The effect of Hepar Magnesium on seasonal fatigue syndrome: A pilot study

Simple item page
dc.contributor.authorBaars, Erik W.
dc.contributor.authorGans, S
dc.contributor.authorEllis, Ernst L.
dc.date.accessioned2024-05-23T18:52:25Z
dc.date.available2024-05-23T18:52:25Z
dc.date.digitized2019-01-23 19:26:39
dc.date.issued2008
dc.description.abstract<h2>Abstract</h2> <p><strong>Objectives:</strong> To evaluate the effect of the anthroposophic drug hepar magnesium D10 intravenously administered on seasonal fatigue symptoms.</p> <p><strong>Design:</strong> Time series with two measurements per week, starting before onset of treatment until three measurements after finishing treatment in a regular way.</p> <p><strong>Settings:</strong> Six anthroposophic general practitioner practices in the Netherlands.</p> <p><strong>Subjects:</strong> Twenty-three (23) patients with seasonal fatigue symptoms.</p> <p><strong>Interventions:</strong> Hepar magnesium D10 intravenously administered every week.</p> <p><strong>Outcome measures:</strong> Mean division of 24 hours in categories: sleep, rest, everyday activities, and activities that require a large effort; fatigue-related single questions: unusual emotional response to events, problems with short-term memory, the degree to which fatigue after effort continues for longer than 2 hours, the degree to which people at the end of the day have a complete lack of energy; and the degree to which people are still fit after the evening meal; Multidimensional Fatigue Index: general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue; subjective experiences with regard to the effect of the treatment. </p> <p><strong>Results:</strong> (1) No changes in division in 24-hour categories were found; (2) pretreatment versus post-treatment analyses (after 1 and 2.5 weeks, at the end of treatment, and 1.5 weeks after the end of treatment) demonstrated overall large statistically significant differences. Eighteen (18) of 22 patients (82%) who completed the final questionnaire judged that treatment overall had been effective for their fatigue symptoms. Nine (9) patients (41%) judged a strong improvement and 9 patients (41%) a light improvement as a result of the treatment. Four (4) patients reported no change. On average, patients received treatment 4.5 times.</p> <p><strong>Conclusions:</strong> There are clear indications that hepar magnesium D10 intravenously administered can have a positive effect on subsyndromal seasonal affective disorder symptoms of fatigue. A more controlled trial is indicated to study the (long-term) effects of hepar magnesium.</p> <p><strong>Citation</strong>: Baars, E. W., Gans, S., &amp; Ellis, E. L. (2008). The Effect of Hepar Magnesium on Seasonal Fatigue Symptoms: A Pilot Study. <em>The Journal of Alternative and Complementary Medicine</em>, <em>14</em>(4), 395–402. <a href="https://doi.org/10.1089/acm.2007.0569" target="_blank">https://doi.org/10.1089/acm.2007.0569</a></p>
dc.identifier.citationBaars, E. W., Gans, S., & Ellis, E. L. (2008). The Effect of Hepar Magnesium on Seasonal Fatigue Symptoms: A Pilot Study. The Journal of Alternative and Complementary Medicine, 14(4), 395–402. https://doi.org/10.1089/acm.2007.0569
dc.identifier.doihttps://doi.org/10.1089/acm.2007.0569
dc.identifier.externalUrl/library/2019/1/4/the-effect-of-hepar-magnesium-on-seasonal-fatigue-syndrome
dc.identifier.urihttps://hdl.handle.net/20.500.14430/308
dc.subject.otherseasonal fatigue syndrome
dc.subject.otherHepar magnesium
dc.titleThe effect of Hepar Magnesium on seasonal fatigue syndrome: A pilot study
dspace.entity.typePublication
oaire.citation.titleJACM
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Baars_The Effect of Hepar Magnesium on Seasonal_2008.pdf
Size:
585.26 KB
Format:
Adobe Portable Document Format
Download
Collections
01 Anthroposophic medicine (AM), therapies and health